Table 3.
Analysis of relevant clinical variables and time since lung cancer diagnosis until OE
| Time until OE (months) | |||
|---|---|---|---|
| Variables | N | Mean (95% CI) | P |
| Age | |||
| <66 | 39 | 3.95 (1.93–5.96) | 0.011* |
| ≥66 | 43 | 9.18 (4.45–13.91) | |
| Gender | |||
| Male | 60 | 7.63 (4.1–11.1) | 0.429* |
| Female | 22 | 3.95 (0.8–7.09) | |
| Histology | |||
| NSCLC | 68 | 7.65 (4.5–10.8) | 0.016* |
| SCLC | 11 | 1.36 (0.0–3.5) | |
| Stage at LC diagnosis | |||
| Non metastatic | 12 | 13.67 (7.8–19.5) | 0.002* |
| Metastatic | 70 | 5.44 (2.5–8.4) | |
| Treatment at OE | |||
| No treatment | 45 | 0.38 (0.1–0.7) | <0.001** |
| Systemic Therapy | 35 | 13.86 (8.6–19.1) | |
| SBRT | 2 | 21.50 (0.0–53.3) | |
| Type of OE | |||
| Cardiovascular | 26 | 5.6 (1.8–9.3) | |
| Neurologic | 43 | 8.0 (3.4–12.6) | 0.551** |
| Respiratory | 13 | 4.3 (1.9–6.7) | |
| Year | |||
| 2019 | 36 | 1.0 (0.1–8.3) | 0.670* |
| 2020 | 46 | 1.5 (0.1–10.3) | |
Abbreviations: OE, oncologic emergency; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; SBRT, stereotactic body radiation therapy;
* Mann-Whitney U test
** One-way Anova